Cancer
screening is a detecting a cancer before the sign appears. It includes DNA
tests, blood tests, urine tests, and other tests. It is mainly many types such
as cervical cancer, colorectal cancer, head & neck cancer, breast cancer,
prostate cancer, lung cancer and skin cancer etc. Cervical cancer includes Pap
test and Human papillomavirus (HPV). Colorectal cancer includes sigmoidoscopy
test, stool DNA test, double contrast barium enema, fecal occult blood test
(FOBT) and colonoscopy test. Prostate cancer includes Prostate-specific antigen
(PSA) test and Digital rectal examination (DRE). The major risks associated
with cancer screening techniques are false reassurance, false positives, over
diagnosis and increased testing.
According
to study, “Cancer Screening Market in China
(2018-2023)”
some of the major companies that are currently working in the cancer screening
market in China are F. Hoffmann-La Roche AG, Quest Diagnostics, Qiagen, Abbott
Laboratories, Hologic Inc.
Based
on tests, the cancer screening market is segmented into genomic testing,
imaging, digital pathology, cancer biomarker tests, biopsy and endoscopy etc.
Imaging tests include Computed Tomography (CT) scan, ultrasound, Positron
Emission Tomography (PET) scan, mammography and Magnetic Resonance Imaging
(MRI) scan. Cancer biomarker tests include prostate specific antigen tests,
EGFR mutation tests, Alpha Fetoprotein (AFP) test, HER2 test, Circulating Tumor
Cells (CTC) tests, Cancer Antigen tests (CA 19-9 and CA 125), BRCA tests and
other tests such as CEA tests, ALK tests and KRAS mutation tests.
The
China cancer screening is mainly driven by increase in the aging population
followed by adoption of innovative screening technologies, increasing number of
biopharmaceutical companies, growing research & development, rapid rise in
the number of cancer cases, growing attentiveness among people, rising adoption
of high-scale investments, advent of efficacious genetic tests, rising favourable
government policies, potential product pipeline, increase in the patient pool. However
some of the restraints are lack of screening guidelines, inadequate healthcare
access and high screening tests costs.
The
drugs at inferior prices along with ensuring affordability and accessibility are
expected to be a major threat in the country. The people of country demand a
transparency as provision of perfect & proper treatment to big opportunity
for this market. Nowadays, the government is focusing on several cancer control
programs for alleviating cancer prevalence. These programs include prevention,
early diagnosis & treatment. Early diagnosis programs contain screening for
cervix & breast cancer while prevention programs contain anti-smoking
operations and immunization against hepatitis. The Cancer Screening Program in
Urban China (CanSPUC) is a government initiated program for assessing the continuing
sustainability of cancer screening in country.
In
the past decade, China's demand for cancer screening has developed at a rapid
pace. Cancer is one of the most important healthcare burdens in country. The
Chinese economy preserves a high pace of augmentation stimulated by the
consecutive enhance in capital venture. Lung cancer screening holds largest
market share in region, which is mainly driven by adult males. It is expected
that the China cancer screening market will be reached US $1.5 billion, at a
CAGR of 14 %, by 2023. In the near future, it is predicted that the market to
grow rapid pace owing to massive impact of rising cancer diseases
by tobacco.
To
know more, click on the link below:-
Related
Reports:
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
